Verrica Pharmaceuticals (VRCA) Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Do insiders and institutionals hold more shares of VRCA or FBIO?

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate VRCA or FBIO?

Verrica Pharmaceuticals currently has a consensus price target of $9.60, suggesting a potential upside of 1,051.77%. Fortress Biotech has a consensus price target of $13.00, suggesting a potential upside of 809.09%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor VRCA or FBIO?

Fortress Biotech received 159 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. However, 64.23% of users gave Verrica Pharmaceuticals an outperform vote while only 63.55% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
Verrica Pharmaceuticals	Outperform Votes 167 64.23%	Underperform Votes 93 35.77%
Fortress Biotech	Outperform Votes 326 63.55%	Underperform Votes 187 36.45%

Does the media refer more to VRCA or FBIO?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 6 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.00 beat Fortress Biotech's score of 0.31 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is VRCA or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to Verrica Pharmaceuticals' net margin of -625.06%. Fortress Biotech's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-625.06%	-591.84%	-141.63%
Fortress Biotech	-84.53%	N/A	-33.17%

Which has more risk and volatility, VRCA or FBIO?

Verrica Pharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Which has higher earnings and valuation, VRCA or FBIO?

Fortress Biotech has higher revenue and earnings than Verrica Pharmaceuticals. Fortress Biotech is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$5.12M	7.42	-$67M	-$1.83	-0.46
Fortress Biotech	$84.51M	0.39	-$60.64M	-$3.05	-0.47

Summary

Fortress Biotech beats Verrica Pharmaceuticals on 10 of the 17 factors compared between the two stocks.